Mebeverine Milpharm

Mebeverine Hydrochloride, the active ingredient in Mebeverine Milpharm, is an antispasmodic (smooth muscle relaxant) presented as an oral dosage form for systemic use. It is employed to relieve gastrointestinal smooth‑muscle spasms associated with functional bowel disorders such as irritable bowel syndrome.

GNH USA supplies Mebeverine Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mebeverine Hydrochloride acts on the gastrointestinal smooth‑muscle pathway to alleviate spasm‑related conditions.

- Irritable bowel syndrome: reduces abdominal pain and cramping by relaxing intestinal smooth muscle. - Functional bowel disorders: improves bowel habit regularity and decreases discomfort. - Spastic colon: alleviates colonic spasms and associated bloating.

Mebeverine Milpharm may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild, transient feeling of stomach upset. - Headache: occasional dull or throbbing pain. - Dizziness: brief episodes of light‑headedness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Severe abdominal pain: persistent pain not relieved by the medication. - Cardiac arrhythmia: irregular heartbeat reported rarely.

When prescribing Mebeverine Milpharm, clinicians should consider several safety and handling points.

- Assess medical history: confirm absence of known hypersensitivity to mebeverine or excipients. - Monitor renal function: adjust use in patients with severe renal impairment. - Use caution in elderly: increased susceptibility to dizziness or hypotension. - Avoid concurrent use with potent CYP3A4 inhibitors: may alter drug levels. - Store at room temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Mebeverine Hydrochloride can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentration, risk of toxicity. - Anticholinergic agents (e.g., atropine): additive antispasmodic effect may cause excessive gut relaxation.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., tricyclics): may enhance dizziness. - Antihistamines: potential increase in dry mouth. - Diuretics: monitor for orthostatic hypotension.